Genmab Appoints Séverine Lemoine as General Manager for France

Local Media Release – France

 Copenhagen, Denmark – December 3, 2025

Genmab A/S (Nasdaq: GMAB) today announced the appointment of Séverine Lemoine as General Manager for France. The announcement advances the company’s work to expand its presence in Europe and bring its innovative antibody-based medicines to more patients with cancer.

Founded in 1999 in Copenhagen, Genmab is an international biotech company that specializes in antibody-based science. As part of the company’s growth into commercial markets in Europe, Genmab is now building its presence in France.

As General Manager, Séverine will lead Genmab’s operations in France, including building the company’s local footprint, driving the success of future product launches, and contributing positively to the local life sciences ecosystem.

“We are delighted to welcome Séverine to Genmab at this pivotal stage of our growth in Europe,” said Brad Bailey, Executive Vice President and Chief Commercial Officer of Genmab. “Séverine’s experience building high-performing teams and successfully launching oncology products, combined with her extensive knowledge of the French healthcare landscape, make her a highly qualified leader to help guide Genmab’s introduction to this important market.”

Séverine brings more than 20 years of leadership experience in oncology across biotech and pharma, having held senior leadership positions at Moderna, Seagen, Roche, Novartis, and AstraZeneca. Séverine joins Genmab with a strong track record of building business operations for biopharma companies in France, developing high-performing teams, and successfully launching new oncology medicines, with focus in women’s cancers.

“I am honored to join Genmab, a leader in antibody innovation with a compelling purpose to transform patients’ lives,” said Séverine Lemoine. “France has long been a center of excellence in oncology research and patient care, and together with our talented team and partners, I look forward to building Genmab's presence in France and delivering meaningful impact for patients and the healthcare community.”

Séverine holds a Doctor of Pharmacy degree (Université René Descartes – Paris V, 2000) and earned a Master’s in Marketing Management in 2001 from the ESSEC Healthcare Chair (ESSEC Business School).

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO^®) antibody medicines. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:           
Caitlin Craparo, Vice President, Global Communications & Corporate Affairs
T: +1 609 255 7397; E: cacr@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations 
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®